All Autoimmune disease articles – Page 3
-
ArticleUnlocking the potential of smart antibodies
Biolojic Design is redefining antibody therapies by creating “programmable” antibodies that intelligently target well-validated autoimmune and oncology pathways. In this Q&A, CEO and founder Yanay Ofran, PhD, describes Biolojic’s groundbreaking approach, which leverages AI and machine learning to design antibodies capable of adjusting their behaviour based on their biological environment. ...
-
NewsMechanism linking obesity to inflammation uncovered
This study is first to demonstrate with statistical certainty that human visceral adipose tissue accumulated in the abdominal cavity secretes more extracellular vesicles.
-
ArticleExploring the potential of ADCs beyond oncology
Antibody Drug Conjugates (ADCs) are already deployed as part of the roster of oncology treatments, but here, Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, looks into their potential to help treat a whole range of other diseases and conditions. He discusses the barriers and enablers ...
-
ArticleSupercharging conventional monoclonal antibodies
In this Q&A, Krishna Polu and Dennis Pedersen, senior leaders of Commit Biologics, which is backed by Novo Holdings and Bioqube Ventures, elucidate how their technology differs from other existing therapeutic platforms and highlight its implications for the treatment of both cancer and autoimmune disease.
-
ArticleTranslating ‘nature’s cues’ into breakthrough immunotherapies
Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming ...
-
NewsRare types of helper T cells uncovered
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
-
ArticleTreating immune-mediated diseases with nanoparticles
In this Q&A, we had the privilege of speaking to COUR Pharmaceuticals’ CEO John Puisis. He offers insights into how their innovative immune-modifying nanoparticle platform differs from traditional approaches for treating immune-mediated diseases.
-
NewsNew method to predict effectiveness of MSCs for cartilage repair in vitro
Topological defects in mesenchymal stromal cell self-assembly could suggest their potential for cartilage regeneration.
-
ArticleThe promise of therapeutics from molecules within our body
In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches.
-
NewsNew study challenges assumptions about the development of RA
Scientists have discovered that each rheumatoid arthritis patient possesses a unique and diverse set of ACPAs.
-
NewsThe genetic mutation causing the development of psoriatic arthritis
Mutation in two copies of the IKBKB gene leads to abnormal function of regulatory T cells, causing psoriatic arthritis.
-
NewsNew insights into PD-1 formation could greatly improve treatments
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.
-
NewsCombatting osteoarthritis with cartilage replacement therapy
Limb bud progenitor cells efficiently generated new cartilage in osteoarthritis patients, which could lead to cartilage replacement therapy.
-
ArticleUnlocking the power of stem cell therapy
In this Q&A, founder of Scheer Medical Wellness Dr Alexander Scheer shares his insights, discussing the current challenges in stem cell therapy and how these can be addressed, the advancements in delivery techniques, and stem cells’ overall potential in regenerative medicine.
-
NewsImproving treatments for rheumatoid arthritis patients
Researchers found that resolvinT4 restores protective macrophage biological activities in rheumatoid arthritis patients.
-
ArticleHow 3D human tissue models are transforming drug discovery
In this Q&A, Keith Murphy, CEO of Organovo, discusses how the shift from animal models to 3D human tissues can transform the preclinical space. Among his many insights, he details the limitations of animal models, how Organovo’s 3D human tissue models facilitate a deeper understanding of genetic expression within specific ...
-
NewsChanges in CD4+ T cells associated with autoimmune diseases
Genetic factors that promote disease development accumulated in CD4+ T cells exhibiting specific gene programmes.
-
NewsDelivering a human monoclonal IgG1 antibody to the brain
Adding a biodegradable polymer at the hinge and near hinge regions of trastuzumab enabled its movement across the blood-brain barrier.
-
News
New insights into the functions of inflammasomes
For diseases mediated by NLRP3, AIM2, NLRC4, and Pyrin, understanding inflammasome biology could identify therapeutic targets.
-
ArticleNew technology optimises mesenchymal stem cell extraction
A continuous sorting technique of stem cells on a DLD microfluidic platform may greatly advance cell therapy.
- Previous Page
- Page1
- Page2
- Page3
- Page4
- Next Page